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Abstract
Background—Global data on durability of first-line antiretroviral therapy (ART) in children 
with HIV is limited. We assessed time to switch to second-line therapy in 16 European countries 
and Thailand.
Methods—Children <18-years initiating combination ART (≥2 nucleoside reverse transcriptase 
inhibitor (NRTI) plus non-NRTI (NNRTI) or boosted-protease inhibitor (PI)) were included. 
Switch to second-line was defined as: (i) change across drug class (PI to NNRTI or vice versa) or 
within PI-class plus change of ≥1 NRTI; (ii) change from single to dual PI; or (iii) addition of a 
new drug class. Cumulative incidence of switch was calculated with death and loss-to-follow-up as 
competing risks.
Results—Of 3,668 children included, median [IQR] age at ART initiation was 6.1 [1.7,10.5] 
years. Initial regimens were 32% PI, 34% nevirapine (NVP), 33% efavirenz-based. Median 
duration of follow-up from ART start was 5.4 [2.9,8.3] years. Cumulative incidence of switch at 5 
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years was 21% (95% CI 20, 23), with lowest incidence in Russia/Ukraine and highest in UK/
Ireland. Median time to switch was 30 [15, 58] months, two-thirds of switches were related to 
treatment failure. In multivariable analysis, older age, severe immunosuppression and higher viral 
load at ART start, and NVP-based initial regimens were associated with increased risk of switch. 
Among those switched, 65% had viral load <400c/mL at 12-months after start of second-line ART.
Conclusions—One in five children switched to second-line by 5 years of ART, with two-thirds 
failure related. Advanced HIV, older age and NVP-based regimens were associated with increased 
risk of switch.
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Introduction
Worldwide, an estimated 2.1 million children aged<15 years were living with HIV in 2016, 
of whom 43% were accessing antiretroviral therapy (ART), with coverage expected to 
increase further[1]. Sustaining long-term viral suppression on ART throughout childhood 
and adolescence is a challenge[2]. Observational cohorts in middle and high-income 
countries with routine viral load monitoring have reported cumulative risk of virological 
failure in children ranging from 18% to 40% at 3 to 5 years after ART start[3–6]. As 
children currently require lifelong treatment, subsequent ART options will inevitably be 
required, and therefore programme planning and forecasting demand for paediatric 
formulations are needed.
There remain limited and often conflicting estimates on the use of second-line ART in 
children, with wide variations in both clinical trials and observational cohorts, ranging from 
2% to 23% switching at 5 years after ART initiation[6–11]. This reflects variation in initial 
regimens, monitoring and switching strategies, availability of alternative regimens across 
studies and settings, and differences in the definitions of ‘switch’ used. Some studies have 
restricted switch analyses to children with confirmed or unconfirmed virological 
failure[3,12], which may under-estimate the broader use of second-line treatment due to 
clinical and/or immunological failure, or major treatment limiting toxicities[6,13].
In this study, we assessed time to switch to second-line ART for any cause and associated 
factors in the context of routine viral load monitoring, within the European Pregnancy and 
Paediatric HIV Cohort Collaboration (EPPICC), composed of cohorts across 16 European 
countries and Thailand. These cohorts offer long-term follow-up data to assess incidence of 
switch in routine-care settings across regions, which may inform other countries moving 
towards viral load monitoring[14].
Methods
Nineteen paediatric HIV observational cohorts across 17 countries contributed to an 
individual patient data meta-analysis carried out in December 2014. Routine demographic, 
clinical, laboratory and treatment related data were pooled electronically using a modified 
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HICDEP protocol (www.hicdep.org). Children were included in this analysis if they were 
aged <18 years at start of a ‘standard’ combination ART regimen, defined as ≥2 nucleoside 
reverse-transcriptase inhibitors (NRTI) plus a non-NRTI (NNRTI) or boosted protease 
inhibitor (PI). Children who participated in clinical trials of switching strategies or treatment 
interruption were excluded. All cohorts received local ethics approval to transfer 
anonymised data for this study.
Switch to second-line ART was defined as either (i) change across drug class (from NNRTI 
to PI or vice versa) or change within PI-class, plus change of ≥1 NRTI; (ii) change from 
single to dual PI; or (iii) an addition of a new drug class. Switches with documented reasons 
of simplification, tuberculosis prophylaxis or pregnancy were ignored. This stringent 
definition of switch was used to reflect World Health Organization (WHO) and European 
guideline recommendations on the management of treatment failure in children[15–17]. In 
sensitivity analyses, we (i) ignored any switches during the first 6 months after ART 
initiation as these were unlikely to be related to treatment failure, (ii) relaxed our switch 
criteria by not requiring a change of ≥1 NRTI when switching across drug class or within PI-
class, if the reason for switch was reported as failure, as some settings may need to preserve 
NRTIs.
Among patients meeting our definition of switch we described the reasons reported for 
switching and explored evidence for clinical failure in those with missing reason (defined as 
(i) viral load>1,000cps/mL; (ii) new CDC B/C event; or (iii) no CD4 gain from ART 
initiation, within the 6-months prior to switch). We describe the characteristics at time of 
switch and virological response (<400 c/ml) at 12 and 24-months after switch.
Time to switch was summarised using cumulative incidence, accounting for competing risks 
of death and loss to follow-up (LTFU). Children were at risk from ART start until the 
earliest of switch, death, last visit in paediatric care or 21st birthday. Cohorts contributed 
follow-up data through to December 2013 except for Germany (until April 2012), Portugal 
(September 2013) and Romania (October 2013). LTFU was defined as children not known to 
have died or transferred to another clinic, whose last visit was more than two years before 
the cohort censoring date, or children reported as LTFU by their cohort.
The associations between time to switch and characteristics at ART initiation were 
investigated using competing risks proportional hazards regression[18]. In univariable 
analysis, associations with the following factors at the start of ART were explored: age, sex, 
immunosuppression (WHO 2007 classification severe vs. non severe for age[19]), viral load 
(VL), CDC stage (C vs N/A/B), initial ART regimen, calendar year (1997-<2004, 2004-
<2008, ≥2008), region of cohort (UK & Ireland, Thailand, Russia & Ukraine (Eastern 
Europe) and remaining countries (Central & Western Europe)). The final multivariable 
model was selected using backwards elimination (exit probability p=0.05), with baseline 
hazard stratified by region. Region was not included in the multivariable model as a 
covariate due to evidence of non-proportional hazards between regions. The functional form 
of continuous age was explored using regression splines. Differences in the effect of initial 
regimen on switch by age and year at ART start were explored. A sub-group analysis in 
children aged <3 years in the UK/Ireland compared NVP+3NRTIs (rarely used in other 
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regions) to other initial regimens. P-values are two-sided, and analyses were carried out 
using STATA v14.1 (Stata Corporation, College Station, Texas, USA).
Results
Of 3,953 children who initiated ART, 3,668 (93%) met the study inclusion criteria (88 were 
excluded due to participation in clinical trials, 197 initiated on non-standard regimens). Half 
of the children were male; 90% were perinatally infected (Table 1).
The three largest cohorts were from the UK/Ireland (29% of children), Thailand (19%), and 
Ukraine (13%). Earliest year of ART initiation ranged from 1997 in UK/Ireland to 2002 in 
Thailand. Approximately one-third of children started ART on efavirenz (EFV), nevirapine 
(NVP) or PI-based regimens (93% lopinavir/ritonavir). Median age at the start of ART was 
6.1 [IQR 1.7,10.5] years, and lower in children who initiated on PI- and NVP-based 
regimens than EFV-based regimens (Table 1). A larger proportion of children initiating on 
PI-based regimens started treatment in later calendar years (≥2008) compared to other 
regimens. Children in the UK/Ireland and Thailand were more likely to initiate on NNRTI-
based regimens compared to other regions where more children started on PI-based 
regimens. The median duration of follow-up after start of ART was 5.4 [2.9,8.3] years. The 
median gap between VL measurements after ART start varied across regions: 36, 26 and 
13-14 weeks in Eastern Europe, Thailand and the rest of Europe, respectively.
Switch to second-line
Overall, 820 (22%) children met the definition of switch while 71 (2%) died and 374 (10%) 
were LTFU before switching. There were significantly fewer patients LTFU in the UK/
Ireland, more deaths in Thailand, and fewer patients switching in Eastern Europe (p<0.001) 
(Figure S1). Among those who switched, the median time from ART start to switch was 30 
[16,58] months, the majority (72%) switching from an NNRTI- to a PI-based second-line 
regimen.
The overall cumulative incidence of switch was 14% (95% CI 13-15%) at 3 years, 21% 
(20-23%) at 5 years and 27% (26-29%) at 7 years after ART start. The cumulative incidence 
varied across regions, and these regional differences changed over time (Figure 1). At 1 year 
after ART start, Thailand and Eastern Europe had lowest cumulative incidence of switch at 
2% (1-3%), but it rapidly increased in Thailand to 16% (13-19%) by 3 years, a similar level 
to Western & Central Europe and UK/Ireland, and plateaued thereafter. At 5 years after ART 
initiation, the cumulative incidence of switch was lowest in Eastern Europe at 12% (9-16%), 
and ranged from 20-25% in the other regions.
Reasons for switch
Among those switched to second-line ART, 652 (80%) had a documented reason for switch 
available, of which 63% were “treatment failure”, 11% “toxicity” and the remainder for 
“other reasons” including non-compliance. Clinicians were more likely to report toxicity as 
the reason for switching from a PI-based regimen, whereas NVP-based regimens were more 
likely to be for failure (p<0.001) (Figure 2). Among the 168 (20%) children with missing 
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reason for switch, 56% were likely to be due to treatment failure based on their clinical, 
immunological and virological data in the 6 months prior to switch. There was no significant 
difference in time to switch between those with and without a reason for switch reported 
(p=0.5).
Factors at ART initiation associated with switch
Children who initiated on NVP-based regimens had over two-fold increased risk of switch 
compared to children starting on PI-based regimens (adjusted sub-hazard ratio (sHR) 2.47, 
95% CI 1.86-3.27, p=0.001), while those starting EFV-based regimens had a smaller 
increased risk (sHR 1.53 (1.16-2.02), p=0.002) (Table 2). In a sub-group analysis of UK/
Ireland children aged <3 years, there was no difference in risk of switch between children 
taking NVP with a 3-NRTI (n=40) versus 2-NRTI (n=41) backbone (sHR 0.99 (0.51, 1.91), 
p=0.97), with both groups at increased risk of switch compared to those starting a PI-based 
regimen. The effect of age on hazard rate of switch was linear, with a 5% increase in risk of 
switch per year increase in age at start of ART (sHR 1.06, 95% CI 1.03-1.08, p<0.0001) 
(Figure 3). Severe immunosuppression and higher VL at ART start were associated with 
increased risk of switch. After adjusting for these factors, sex, CDC stage and calendar year 
at ART initiation were not associated with risk of switch. There was no evidence of an 
interaction between age at ART start and initial regimen (p=0.3).
Sensitivity analyses
When 63 switches in the first 6-months of ART were excluded, the cumulative proportion of 
switch was lower, at 19% (95% CI, 18-21%) at 5 years after ART start. Including switches 
across class or within PI class without a simultaneous change in ≥1NRTI, if the reported 
reason for switch was failure, increased the number of children switching to second-line by 
95 and the cumulative proportion of switch at 5 years to 24% (95% CI, 22-25%). Additional 
switches were predominately from Thailand (51%), and from an NNRTI to a PI-based 
regimen (82%). The median time to switch was comparable to that observed in the main 
analysis. In multivariable analyses, the same factors remained associated with switch, with 
limited change to the point estimates, apart from the risk of switch for NVP-based regimens 
was reduced to 2.13 and 2.16 respectively. In addition, risk of switch was increased for 
children starting ART before 2004 when ignoring switches <6 months (data not shown).
Characteristics at time of switch and response to second-line ART
Among those switched to second-line, median age at switch was 11 [6,15] years, VL 
(n=671) was 4.1 [3.0,4.9] log10 copies/mL and CD4% (n=682) was 20 [11,29] %. The 
majority of children (72%) received a PI-based second-line regimen (lopinavir/ritonavir 
(57%), atazanavir (11%), darunavir (5%)), and <1% (n=7) received an integrase inhibitor 
(INSTI)-based regimen. The median duration of follow-up after start of the second-line 
regimen was 3.8 (1.8,6.5) years; among those with a VL measurement at 12 (n=561) and 24 
(n=480) months after start of second-line, 65% and 69% were suppressed at <400 
copies/mL, respectively.
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Discussion
This study of time to switch to second-line ART for any cause in children with routine viral 
load monitoring is the largest to date. It includes many national cohorts across Europe[5,20], 
benefits from long duration of follow-up (over 5 years) and low levels of mortality and loss-
to-follow-up. There are four key findings from our study. First, approximately 80% of 
children remained on their first-line regimen at 5 years after ART initiation (allowing for 
minor drug modifications and treatment simplifications). One-in-five children met our 
definition of switch at 5 years, although there were significant regional variations in the 
proportion switching, with lowest estimates of 12% in Eastern Europe and highest of 25% in 
the UK and Ireland.
Second, older age at start of ART was associated with increased risk of switch, with no 
evidence that this effect varied by initial regimen. Previous studies have reported increased 
risk of virological failure among children starting ART at older ages[21]. While our outcome 
was switch for all-causes, over two-thirds of the switches were failure-related. The higher 
risk of switch in older children may reflect increased risk of failure as well as greater 
treatment options and/or willingness to switch adolescents experiencing failure compared to 
younger children. A recent global meta-analysis (including EPPICC), of approximately 
100,000 children on ART, the large majority from sub-Saharan Africa, also reported 
increased risk of switch to second-line with older age at ART start[22]. This highlights the 
need to consider novel adherence or support interventions for children initiating treatment at 
older ages, particularly adolescents[23]. This may include treatment simplification strategies 
such as the ‘weekends off’ short-cycle therapy. The BREATHER trial randomised 
adolescents virologically suppressed on EFV-based regimens to continuous treatment versus 
short treatment cycle of 5 days on and 2 days (weekends) off-ART. The latter group reported 
high acceptability[24], maintained high levels of viral suppression, with low rates of switch 
at 48 and 144 weeks of follow-up and reported no difference in inflammation markers 
[25,26].
Thirdly, children initiating a NVP-based regimen had increased risk of switch, as did those 
starting EFV (although to a lesser degree), compared to those starting PI-based regimens. 
This is consistent with findings from previous studies showing increased risk of switch to 
second-line in NVP- versus PI-based regimens[3,5,27]. This could partly reflect the 
reluctance of clinicians to switch children failing a PI-based regimen due to the difficulty in 
deciding what to switch to, and recommendations to first address adherence issues due to the 
high resistance barrier[17]. However, studies have also shown increased risk of virological 
failure for NVP- versus PI-based regimens[5,28], and a higher proportion of the switches 
from NVP-based regimens in our cohort were reported as failure-related. These findings 
support PENTA and US guideline recommendations to consider PI-based first-line regimens 
in all children (aged>14 days) and adolescents[17,29]. Nonetheless NVP remains a widely 
used, low-cost, essential drug option for children in resource-limited settings with poor 
access to PIs[22,30]. It is important to note that the majority of children who initiated NVP 
in our cohort remained on it at 5 years (73%), suggesting those who tolerated and responded 
to NVP did achieve long durability on this first-line regimen.
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Outside of Eastern Europe, our estimates of switch at 5 years were remarkably similar across 
regions, despite wide variations in the initial regimens used, and age and immune status at 
start of ART. Since, severe immunosuppression at ART initiation was confirmed as a risk 
factor for switch in our study[11], one may have expected higher switch rates in Thailand 
which had both the highest proportion of children starting NNRTI-based regimens (93%) 
and who were severely immunocompromised. The lower levels of switch observed in 
Thailand most likely reflect differences in frequency of viral load testing, as well as 
availability/readiness to switch to second-line regimens.
Comparison of unadjusted cumulative incidence estimates of switch across studies and 
contexts is challenging as the distributions of risk factors in heterogeneous populations is not 
taken into account. Notwithstanding this limitation, our overall estimate of switch to second-
line of 21% at 5 years is comparable to recent findings from the Asia Pacific cohort, which 
reported 23% switch at 5 years among children with routine viral load monitoring[11]. 
Importantly the authors report that children without viral load monitoring had a 53% lower 
incidence of switch compared to children with viral load monitoring. As more countries shift 
towards routine or targeted viral load monitoring[30], the use of second-line ART, which is 
currently very low (≤3%) in settings without viral load monitoring[22], is expected to 
increase following improved detection of treatment failure and efforts to improve availability 
of PI-based and INSTI-based regimens in paediatric formulations[31]. The global use of 
second-line ART may then reach similar levels to that observed in our cohort.
The clinical implication of the shift to routine viral load testing remains unclear. The 
PENPACT-1 trial reported no difference in clinical outcomes when switching children early 
or late, at high (30,000 copies/ml) or low (1000 copies/ml) viral load levels, although the 
trial was conducted mainly in high-income countries. However, earlier switch did minimise 
the accumulation of drug resistance mutations in those initiating on NNRTI-based 
regimens[7,32]. Similarly, recent studies of adult patients in sub-Saharan African (the large 
majority initiated on NNRTI-based regimens) have reported that delayed switch to second-
line after prolonged virological failure was associated with accumulation of resistance 
mutations which limited the NRTI options for second-line ART[33], as well as increased 
risk of failure, morbidity and mortality on second-line[12,34,35]. These findings are likely to 
be generalisable to children in such settings. More information on accumulation of drug 
resistance mutations whilst on failing PI-based regimens is needed.
Fourthly, over two-thirds of children in our cohort achieved viral suppression at 12 and 24 
months after switch to second-line. This is broadly consistent with the prevalence of 
suppression at 1 year after switch reported in other paediatric cohorts [36–38]. However 
one-third of patients experienced viremia. It is unclear if this is due to poor adherence or 
resistant virus. Further studies on the clinical outcomes on second and third-line ART in 
children and adolescents are warranted.
There are some important limitations to this study. First, 20% of children switched to 
second-line had no reported reason for switch. Although for these children we used data on 
clinical status, CD4 and VL in the 6 months before switch to assess likelihood of the switch 
being failure-related; this may not reflect the true reason for switch. Second, there are 
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unmeasured potential confounders including exposure to maternal/infant antiretroviral 
prophylaxis, adherence, resistance profile and availability of alternative regimens, all of 
which may influence the probability of switch.
In summary, in our cohort of children with routine viral load monitoring, a fifth had 
switched to second-line while the large majority remained on their first-line regimen at 5 
years of ART. These estimates provide an insight on the expected use of second-line regimen 
as the global paediatric HIV population matures and access to viral load monitoring 
expands. A commitment to the availability of affordable paediatric drugs with high 
resistance barriers[39, 40] and low pill burden will be essential to ensure these needs are 
met[31].
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Summary
One in five children in this European and Thai paediatric HIV cohort collaboration 
switched to second-line ART by 5 years of therapy. Two-thirds of switches were due to 
treatment failure. Nevirapine (NVP)-based regimens were associated with increased risk 
of switch.
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Figure 1. Cumulative incidence of switch to second-line ART by region
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Figure 2. Reasons reported for switch to second-line ART, by initial ART regimen
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Figure 3. Relative hazard of switch by age at ART initiation
Footnote: Relative hazard for age predicted from a proportional hazard regression model 
including ART regimen, WHO immunosuppression status and viral load at ART initiation. 
Hazard rate is plotted relative to a child of age 6.7 years (the median age of the cohort), 
dashed lines represent the 95% CI.
Page 14
Clin Infect Dis. Author manuscript; available in PMC 2018 August 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Page 15
Table 1
Characteristics of children at ART initiation by initial ART regimen
bPI
(n=1191)
EFV
(n=1214)
NVP
(n=1263)
Total
(n=3668)
n % n % n % n %
Male 559 47% 589 49% 599 47% 1747 48%
Perinatal infection* 1110 93% 973 80% 1208 96% 3291 90%
Age (years), median [IQR] 3.2 [0.7, 8.4] 9.5 [6.1, 12.6] 3.9 [0.9, 8.5] 6.1 [1.7, 10.5]
     <1 357 30% 4 0% 340 27% 701 19%
    1 - <3 224 19% 67 6% 226 18% 517 14%
    3 - <6 182 15% 220 18% 202 16% 604 16%
    6 -<11 233 20% 474 39% 347 27% 1054 29%
    11+ 195 16% 449 37% 148 12% 792 22%
CDC stage C 146 12% 155 13% 129 10% 430 12%
CD4% in those <5yrs (n=1183/1614), median [IQR] 23 [16, 32] 16 [11, 22] 22 [14, 34] 21 [14, 32]
CD4 count in those≥5yrs (n=1614/2054), median [IQR] 281 [134, 462] 202 [55, 360] 170 [43, 358] 220 [63, 388]
WHO severely immunocompromised (n=2808) 436 48% 634 63% 508 57% 1578 56%
HIV RNA (log10 copies/ml) (n=2518), median [IQR] 5.2 [4.5, 5.3] 5 [4.4, 5.4] 5.1 [4.4, 5.7] 5 [4.4, 5.6]
Calendar year of ART initiation
    1997 - <2004 127 11% 356 29% 516 41% 999 27%
    2004 - <2008 357 30% 477 39% 498 39% 1332 36%
    ≥2008 707 59% 381 31% 249 20% 1337 36%
Region
    UK/Ireland 201 17% 438 36% 436 35% 1075 29%
    Eastern Europe 402 34% 122 10% 108 9% 632 17%
    Central and Western Europe 541 45% 407 34% 321 25% 1269 35%
    Thailand 47 4% 247 20% 398 32% 692 19%
bPI: boosted protease inhibitor; EFV: efavirenz; NVP: nevirapine; ART: antiretroviral therapy; IQR: interquartile range. *Non-perinatal route of 
infection reported as: parenteral (non-injected drug use) (5%), blood products/transfusion (2%), other (1%) or unknown (3%)
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Table 2
Cumulative incidence of switch at 5 years after ART initiation and factors associated with 
switch to second-line ART
Cumulative incidence (%) at 5 
years (95% CI)
Univariable model Multivariable model†
SHR (95% CI) P aSHR (95% CI) P
First-line ART regimen
   Boosted PI+NRTI 12 (10 - 15) 1 <0.0001 1 <.0001
   EFV+2NRT 23 (20 - 26) 1.94 (1.58 - 2.39) 1.53 (1.16 - 2.02)
   NVP+2NRTI 27 (24 - 29) 2.23 (1.83 - 2.73) 2.47 (1.86 - 3.27)
Age at ART initiation
   Per 1 year increase - 1.04 (1.03 - 1.06) <0.0001 1.06 (1.03 - 1.08) <0.001
   <1 19 (16 - 22)) 0.85 (0.69 - 1.05) <0.0001 -
   1 - <3 18 (16 - 22) 0.79 (0.62 - 0.99)
   3 - <6 15 (12 - 19) 0.79 (0.64 - 0.99)
   6 - <11 21 (18 - 24) 1
   ≥ 11 32 (28 - 36) 1.45 (1.21 - 1.74)
HIV RNA at ART initiation, c/mL
   <100,000 17 (14 - 20) 0.83 (0.69 - 0.98) 0.03 0.74 (0.61 - 0.90) 0.003
   ≥100,000 21, (19 - 24) 1 1
WHO severely immunocompromised
   No 16 (14 - 19) 1 0.01 1 0.04
   Yes 23 (21 - 25) 1.26 (1.06 - 1.49) 1.23 (1.01 - 1.50)
CDC stage C diagnosis
   No 20 (19 - 22) 1 0.01 -
   Yes 28 (24 - 33) 1.27 (1.05 - 1.54)
Calendar year of ART initiation
   1991 - <2004 27 (24 - 29) 1.53 (1.31 - 1.78) <0.0001 -
   2004 - <2008 20 (18 - 22) 1
   ≥2008 16 (13 - 20) 0.79 (0.64 - 0.98)
Proportional hazards regression model accounting for competing risks of death and LTFU.
†
Multivariable regression model stratified by region.
SHR: Sub Hazard Ratio, aSHR: adjusted Sub Hazard Ratio, ART: Antiretroviral Therapy, PI: Protease Inhibitor, NRTI: Nucleoside Reverse 
Transcriptase Inhibitor, EFV: Efavirenz, NVP: Nevirapine
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